Pew Prescription Project finds growing consumer awareness of drug quality problems
Survey shows that 36% of Americans likely to vote have heard of unsafe ingredients
The Pew Prescription Project (PPP; Washington, DC; a part of The Pew Charitable Trusts) has released a survey showing that more than a third of American “likely to vote” (take heed, Washington!) have heard about drug-quality problems, and of those, a majority (60%) believe that FDA should be doing more about it. PPP released the study just as Senator Michael Bennet (D-CO) introduced the “Drug Safety and Accountability Act,” a bill intended to give FDA more authority in examining drug supply chains and sourcing. In supporting the legislation, Allan Coukell, director of PPP, said that “This bill will help to protect the drug supply chain by strengthening manufacturing quality standards throughout the pharmaceutical industry, which is critical as drug companies increasingly rely on contractors in countries where regulatory standards may be lower than those in the United States.”
The PPP survey shows some well-informed consumers on drug sourcing and quality: while 78% are “extremely/mostly confident” of US manufacturing quality, the percentage goes down to 8% for India and 6% for China.
Overall, 58% of respondents “strongly” support the Bennet legislation, and 31% “somewhat” support it. In addition, 73% “strongly” favor unique IDs on individual drug packages, and 72% “strongly” favor listing ingredient origin on the drug label.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
